Exercise

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

Retrieved on: 
Tuesday, April 2, 2024
Vanderbilt Avenue, TD Securities, Exercise, Form, Telephone, Sale, Attention, Gritstone bio, Form S-3, Vaccine, Equity capital markets, Evercore, Security (finance)

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
  • The accompanying common warrants will be immediately exercisable for shares of common stock or pre-funded warrants in lieu thereof, and will expire on the twelve-month anniversary of the date of issuance.
  • All of the shares of common stock, accompanying common warrants and pre-funded warrants are being offered by Gritstone bio.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

RNWK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RealNetworks, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 2, 2024
Houlihan Lokey, Exercise, Intelligence, Facial recognition, Acquisition, Complaint, Proxy, RealNetworks, Court, Person

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/RNWK .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/RNWK .
  • Plaintiff’s claims arise in connection with the acquisition of the Company by Glaser and Glaser’s investment entities Greater Heights LLC and Greater Heights Acquisition LLC.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Steppe Gold Announces 2023 Annual Financial Results

Retrieved on: 
Monday, April 1, 2024
Tax, Term sheet, Silver, Exercise, Development finance institution, Acceleration, Tres Cruces, Sheet, Gold, Sale, Acquisition, News, Toronto Stock Exchange, Bank statement, TSX, Depreciation, Government, EPC, Mining

ULAANBAATAR, Mongolia, April 01, 2024 (GLOBE NEWSWIRE) -- Steppe Gold Ltd. (TSX: STGO) (OTCQX: STPGF) (FSE: 2J9) (“Steppe Gold” or the “Company”) is pleased to announce its financial results for the year ended December 31, 2023.

Key Points: 
  • ULAANBAATAR, Mongolia, April 01, 2024 (GLOBE NEWSWIRE) -- Steppe Gold Ltd. (TSX: STGO) (OTCQX: STPGF) (FSE: 2J9) (“Steppe Gold” or the “Company”) is pleased to announce its financial results for the year ended December 31, 2023.
  • Average realized prices for the three months and year ended December 31, 2023 were $1,977 and $1,948 per gold ounce and $20 and $21 per silver ounce, respectively.
  • All in Sustaining Cost was $1,281 and $1,140 per ounce sold for the three months and year ended December 31, 2023, respectively.
  • The Company’s consolidated financial results for the year ended December 31, 2023 have been filed on SEDAR+.

TC Energy provides conversion right and dividend rate notice for Series 7 and 8 preferred shares

Retrieved on: 
Monday, April 1, 2024
Exercise, TRP, EDT, News, TC Energy, TSX, Series 7, Donald Duck filmography, Security (finance)

CALGARY, Alberta, April 01, 2024 (GLOBE NEWSWIRE) -- News Release – TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) today announced that it does not intend to exercise its right to redeem its Cumulative Redeemable First Preferred Shares, Series 7 (Series 7 Shares) on April 30, 2024.

Key Points: 
  • CALGARY, Alberta, April 01, 2024 (GLOBE NEWSWIRE) -- News Release – TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) today announced that it does not intend to exercise its right to redeem its Cumulative Redeemable First Preferred Shares, Series 7 (Series 7 Shares) on April 30, 2024.
  • As a result, subject to certain conditions, the holders of Series 7 Shares have the right to choose one of the following options regarding their shares:
    to retain any or all of their Series 7 Shares and continue to receive a fixed rate quarterly dividend, or
    to convert, on a one-for-one basis, any or all of their Series 7 Shares into Cumulative Redeemable First Preferred Shares, Series 8 (Series 8 Shares) of TC Energy and receive a floating rate quarterly dividend.
  • Should holders of Series 7 Shares choose to convert their shares to Series 8 Shares, holders of Series 8 Shares will receive the floating quarterly dividend rate applicable to the Series 8 Shares of 7.379 per cent for the first quarterly floating rate period commencing April 30, 2024 to, but excluding, July 30, 2024.
  • Beneficial owners of Series 7 Shares who do not exercise their conversion right through their broker or other nominee by the deadline will retain their Series 7 Shares and receive the new annual fixed dividend rate applicable to the Series 7 Shares, subject to the conditions stated below.

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Commitment, Research, Obesity, PTE, Exercise, Bariatrics, Patent, Patient, Food and Drug Administration, Weight loss, Travel, Acquisition, FLEX, Prescription, NYU, Food, Security (finance), Insurance, Marketing, Surgeon, C-peptide, Annual report, PMA, NYU Langone Health, Division, United States patent law, FDA, Advertising, Bariatric surgery

IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update.

Key Points: 
  • Specifically, it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819.
  • December 2023: Engaged Maxim Group LLC, to act as the company’s exclusive financial advisor to help identify potential synergistic merger and acquisition partnerships.
  • December 2023: Received U.S. Food and Drug Administration (FDA) PMA supplement approval for its next-generation Lap-Band® 2.0 FLEX, designed to improve the patient experience.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.

Applied UV, Inc. Announces Closing of $2.76 Million Registered Direct and Private Placement

Retrieved on: 
Monday, April 1, 2024
Common stock, Private, Exercise, Form, Telephone, Common, Sale, Attention, Share (finance), Form S-3, Prospectus, P.C, Security (finance)

The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.

Key Points: 
  • The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.
  • In a concurrent private placement, the Company also issued common warrants (“Common Warrants”) to the same investors.
  • Aggregate gross proceeds to the Company from both transactions were approximately $2.76 million.
  • The registered direct offering was being made pursuant to an effective shelf registration statement on Form S-3 (No.

InspireSemi Announces Secured Loans and Closing of Private Placement

Retrieved on: 
Monday, April 1, 2024
Creditor, TSX Venture Exchange, Funding, Exercise, Exchange, Loan, Minority, Loan agreement, HPC, AI, Finance Secretary (India), Advance, PV, Security (finance)

The Loans may be repaid by the Company prior to the Maturity Date at the Company’s option.

Key Points: 
  • The Loans may be repaid by the Company prior to the Maturity Date at the Company’s option.
  • The Loans are secured until repayment by a first ranking security granted by general security agreement (and guaranteed by all subsidiaries) on all of the present and future acquired assets of the Company and its subsidiaries.
  • The Company will, subject to the approval of the TSX Venture Exchange (the “Exchange”), issue a total of 48,911 Bonus Warrants to the Lenders.
  • The terms of the Loan Agreement provide that the Company may receive additional secured loans on the same terms up to a maximum amount of US$3,000,000.

H World Group Limited Announces Put Right Notification for 3.00% Convertible Senior Notes due 2026

Retrieved on: 
Monday, April 1, 2024
Put, FICC, Exercise, CUSIP, Wilmington Trust, DTC, NOTES, PARTIES, Note, Depository Trust Company, Indenture, Debt-to-GDP ratio, National Association, PUT, Security (finance)

SHANGHAI, April 01, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (Nasdaq: HTHT and HKEx: 1179, the “Company” or “H World”), a key player in the global hotel industry, today announced that it is notifying holders of its 3.00% Convertible Senior Notes due 2026 (CUSIP No.

Key Points: 
  • SHANGHAI, April 01, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (Nasdaq: HTHT and HKEx: 1179, the “Company” or “H World”), a key player in the global hotel industry, today announced that it is notifying holders of its 3.00% Convertible Senior Notes due 2026 (CUSIP No.
  • The Put Right expires at 5:00 p.m., New York City time, on Monday, April 29, 2024.
  • The Put Right entitles each holder of the Notes to require the Company to repurchase all or a portion of such holder’s Notes in principal amounts equal to US$1,000 or integral multiples thereof.
  • On the Repurchase Date, the repurchase price will be paid in cash to the holders who exercise the Put Right.

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 1, 2024
Regeneration, Exercise, Exchange, Patient, SAN, Column, Sale, Mortality, LLP, Public expenditure, Security (finance), Cooley LLP, Guggenheim Partners, Crosstalk (biology), P.C, Therapy

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN, SRZNW), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase shares of common stock, pre-funded warrants and accompanying warrants to purchase shares of common stock. If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock. The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.

Key Points: 
  • If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock.
  • The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.
  • The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.
  • Guggenheim Securities, LLC is acting as sole placement agent for the private placement and is being advised by Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, PIN, LTD, Intermountain Health, Radiology, Exercise, Medical imaging, Patient, Health, Fatty liver disease, Action Replay, Policy, Sale, AI, D&O, Google Images, Teleradiology, NANO, GAAP, ARC, Depreciation, Marketing, FDA, Vertebral compression fracture, Hand, Cryptocurrency

PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.

Key Points: 
  • Fourth Quarter 2023 Highlights and Recent Developments:
    Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
  • “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
  • “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
  • During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.